Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAOUL DEVIN NELSON

Allopathic & Osteopathic Physicians Pediatrics Pediatric Nephrology

NPI
1972682540
CMS profile
1188095
Location
SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$211.48

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $211.48 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $211.48 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAOUL DEVIN NELSON

NPI 1972682540 · CMS profile ID 1188095

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Nephrology

SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972682540?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAOUL DEVIN NELSON, NPI 1972682540, CMS profile ID 1188095. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972682540?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RAOUL DEVIN NELSON, NPI 1972682540, CMS profile ID 1188095. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972682540?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RAOUL DEVIN NELSON, NPI 1972682540, CMS profile ID 1188095, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1972682540?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $211.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $71.5010/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087124650 CMS
Novartis Pharmaceuticals Corporation $139.9804/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087124642 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $3.82 1
PY2022 $30.43 2
PY2023 $69.74 1
PY2024 $211.48 2
PY2025 $1,850.79 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $251,671.53 36
PY2024 Principal investigator $323,155.10 45
PY2023 Principal investigator $143,206.45 25
PY2022 Principal investigator $34,814.75 7
PY2021 Principal investigator $86,188.09 9
PY2020 Principal investigator $21,071.22 4
PY2019 Principal investigator $25,818.87 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,200.00 12/27/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830860
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,500.00 12/27/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830865
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,837.50 12/27/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830869
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,200.00 12/27/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830873
Principal investigator 1 AKEBIA THERAPEUTICS INC $241.20 12/27/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830878
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,537.50 12/27/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830882
Principal investigator 1 AKEBIA THERAPEUTICS INC $405.00 12/27/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830886
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,500.00 12/27/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830891
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,700.00 12/27/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830895
Principal investigator 1 AKEBIA THERAPEUTICS INC $800.00 12/27/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830900
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,225.00 12/11/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830727
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,875.00 12/11/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830731
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,200.00 12/11/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830736
Principal investigator 1 ABBVIE INC. $2,750.75 11/14/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1100691875
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,037.50 10/15/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830624
Principal investigator 1 AKEBIA THERAPEUTICS INC $6,525.00 10/15/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830629
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,125.00 10/15/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830633
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,500.00 10/15/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830637
Principal investigator 1 Novartis Pharmaceuticals Corporation $43,133.00 09/26/2024 Non-covered Recipient Entity
UNIVERSITY OF UTAH HUNTSMAN CANCER INSTITUTE
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) No dispute reported 06/30/2026 1089693395
Principal investigator 1 Hoffmann-La Roche Limited $1,900.00 08/06/2024 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1133374852
Principal investigator 1 Hoffmann-La Roche Limited $411.00 08/06/2024 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1133374854
Principal investigator 1 Hoffmann-La Roche Limited $3,200.00 08/06/2024 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1133374856
Principal investigator 1 Amgen Inc. $365.41 07/25/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
Pediatric Multi-Dose No dispute reported 06/30/2026 1096314203
Principal investigator 1 ABBVIE INC. $1,092.50 07/11/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1100691535
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,500.00 06/28/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830577
Principal investigator 1 AKEBIA THERAPEUTICS INC $450.00 06/28/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830581
Principal investigator 1 ABBVIE INC. $204.75 06/05/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1100691485
Principal investigator 1 Amgen Inc. $15,021.00 05/23/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
Pediatric Multi-Dose No dispute reported 06/30/2026 1096314201
Principal investigator 1 Hoffmann-La Roche Limited $1,900.00 05/23/2024 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1133374834
Principal investigator 1 Hoffmann-La Roche Limited $411.00 05/23/2024 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1133374850
Principal investigator 1 ABBVIE INC. $5,642.93 05/08/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1100691405
Principal investigator 1 ABBVIE INC. $68.25 04/25/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1100691397
Principal investigator 1 Hoffmann-La Roche Limited $5,864.00 04/25/2024 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1133374832
Principal investigator 1 Hoffmann-La Roche Limited $411.00 04/25/2024 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1133374836
Principal investigator 1 Hoffmann-La Roche Limited $1,900.00 04/25/2024 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1133374842
Principal investigator 1 ABBVIE INC. $1,547.93 04/04/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1100691369
Principal investigator 1 Hoffmann-La Roche Limited $2,725.00 04/02/2024 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1133374840
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $74,987.00 02/28/2024 Non-covered Recipient Entity
NAPRTCS
A PHASE 3B MULTICENTER OPEN-LABEL TRIAL OF THE SAFETY, TOLERABILITY, AND EFFICACY OF TOLVAPTAN IN INFANTS AND CHILDREN 28 DAYS TO LESS THAN 18 YEARS OF AGE WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) No dispute reported 06/30/2026 1118845486
Principal investigator 1 AKEBIA THERAPEUTICS INC $9,150.00 02/26/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830512
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,850.00 02/26/2024 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1145830516
Principal investigator 1 ABBVIE INC. $341.25 02/22/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1100691351
Principal investigator 1 ABBVIE INC. $8,325.41 02/22/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1100691353
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $75,006.50 02/16/2024 Non-covered Recipient Entity
NAPRTCS
A PHASE 3B MULTICENTER OPEN-LABEL TRIAL OF THE SAFETY, TOLERABILITY, AND EFFICACY OF TOLVAPTAN IN INFANTS AND CHILDREN 28 DAYS TO LESS THAN 12 WEEKS OF AGE WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) No dispute reported 06/30/2026 1118845356
Principal investigator 1 ABBVIE INC. $5,540.55 02/06/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1100691343
Principal investigator 1 Amgen Inc. $14,047.17 01/25/2024 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
Pediatric Multi-Dose No dispute reported 06/30/2026 1096314205